Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Otwock – page 2

61 clinical trials in Otwock, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Otwock at a glance
61
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

61 trials in Otwock

Open in trial search

Non-small cell lung cancer+2

Recruiting

Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Maia Biotechnology Inc.

Pulmonary arterial hypertension

Recruiting

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Cough

Not yet recruiting

A Randomized Dose‑Ranging Study of Nalbuphine Hydrochloride Extended‑Release Tablets in Adults with Refractory Chronic Cough

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nalbuphine Hydrochloride
  • Sponsor:Trevi Therapeutics Inc.

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Ivonescimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Macrogenics Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Macrogenics Inc.

Small cell lung cancer extensive stage

Not recruiting

Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Pharmacosmos A/S

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
  • Sponsor:Merck Healthcare KGaA

Pulmonary arterial hypertension

Not recruiting

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer

Not recruiting

A study testing ASP5541 compared to abiraterone acetate in patients with advanced prostate cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Otwock

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on targeted therapies for various types of cancer, including breast, lung, and colorectal malignancies.

  • Advanced breast cancer treatments with novel drug combinations
  • Non-small cell lung cancer therapeutic approaches
  • Colorectal cancer targeted interventions

Studies evaluating breakthrough treatments for patients with metastatic disease and specific genetic mutations.

02 Pulmonary Medicine

Research focusing on treating pulmonary hypertension and related conditions through innovative therapeutic approaches.

  • Pulmonary arterial hypertension treatments
  • Interstitial lung disease interventions
  • Novel inhaled therapies evaluation

Clinical investigations exploring new treatment options to improve patient outcomes in severe respiratory conditions.

03 Precision Medicine

Advanced trials implementing personalized treatment approaches based on specific genetic markers and patient characteristics.

  • HER2-targeted therapies
  • KRAS mutation-specific treatments
  • Immunotherapy combinations

Studies focused on matching patients with optimal treatments based on their unique genetic profiles.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.